B. Riley Wealth Advisors Inc. Has $2.76 Million Position in Danaher Co. (NYSE:DHR)

B. Riley Wealth Advisors Inc. boosted its holdings in Danaher Co. (NYSE:DHR) by 5.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 11,035 shares of the conglomerate’s stock after acquiring an additional 527 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Danaher were worth $2,760,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of DHR. Benjamin Edwards Inc. raised its holdings in shares of Danaher by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after acquiring an additional 38 shares in the last quarter. Patrick M Sweeney & Associates Inc. raised its holdings in shares of Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after acquiring an additional 40 shares in the last quarter. Trust Co of Kansas raised its holdings in shares of Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after acquiring an additional 40 shares in the last quarter. Abacus Planning Group Inc. raised its holdings in shares of Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after acquiring an additional 40 shares in the last quarter. Finally, Certified Advisory Corp raised its holdings in shares of Danaher by 4.5% during the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock valued at $231,000 after acquiring an additional 40 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 in the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Danaher Trading Down 1.3 %

Shares of NYSE:DHR opened at $274.54 on Wednesday. The stock has a market capitalization of $203.35 billion, a price-to-earnings ratio of 46.53, a PEG ratio of 4.55 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock’s 50-day simple moving average is $270.98 and its two-hundred day simple moving average is $258.24. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm earned $2.05 EPS. The business’s quarterly revenue was down 2.9% on a year-over-year basis. Analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s payout ratio is currently 18.31%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Wells Fargo & Company initiated coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price for the company. Leerink Partners increased their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Evercore ISI increased their price objective on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday. Barclays increased their price objective on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Finally, Stephens initiated coverage on Danaher in a report on Tuesday. They issued an “overweight” rating and a $315.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.